<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381886</url>
  </required_header>
  <id_info>
    <org_study_id>CIDH305X2101</org_study_id>
    <nct_id>NCT02381886</nct_id>
  </id_info>
  <brief_title>A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations</brief_title>
  <official_title>A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132
      mutations.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 6, 2015</start_date>
  <completion_date type="Anticipated">April 17, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident rate of dose limiting toxicities (DLTs)</measure>
    <time_frame>9 months</time_frame>
    <description>To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the safety and tolerability of IDH305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters (AUC, Cmax, Tmax)</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK profile of IDH305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of 2-hydroxyglutarate concentration in patient specimens</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PD profile of IDH305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>30 months</time_frame>
    <description>To assess any preliminary anti-tumor activity of IDH305</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAE)</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the safety and tolerability of IDH305</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Advanced Malignancies That Harbor IDHR132 Mutations</condition>
  <arm_group>
    <arm_group_label>IDH305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDH305</intervention_name>
    <arm_group_label>IDH305</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented IDH1R132-mutant tumors

          -  ECOG performance status â‰¤ 2

        Exclusion Criteria:

          -  Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with
             the exception of glioma patients)

          -  Medical conditions that would prevent the patient's participation in the clinical
             study due to safety concerns or compliance with clinical study procedures such as the
             presence of other clinically significant cardiac, respiratory, gastrointestinal,
             renal, hepatic or neurological disease.

          -  Acute Promyelocytic Leukemia

          -  Women who are pregnant or lactating

        Other protocol-defined Inclusion/Exclusion may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute SC (1)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center- New York Presbyterian Onc Dept.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center - Hematology</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDHR132 mutations</keyword>
  <keyword>IDH305</keyword>
  <keyword>IDH</keyword>
  <keyword>IDH1</keyword>
  <keyword>AML</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myeloid</keyword>
  <keyword>Acute</keyword>
  <keyword>MDS</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Glioma</keyword>
  <keyword>Oligodendroglioma</keyword>
  <keyword>Astrocytoma</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

